The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo
Open accessAbstract
Ovarian cancer is the most lethal gynecologic cancer in women. Its high mortality rate (68%) reflects the fact that 75% of patients have extensive (>stage III) disease at diagnosis and also the limited efficacy of currently available therapies. Consequently, there is clearly a great need to develop improved upfront and salvage therapies for ovarian cancer. Here, we investigated the efficacy of metformin alone and in combination with cisplatin in vivo. A2780 ovarian cancer cells were injected intraperitoneally in nude mice; A2780-induced tumors in nude mice, when treated with metformin in drinking water, resulted in a significant reduction of tumor growth, accompanied by inhibition of tumor cell proliferation (as assessed by immunohistochemical staining of Ki-67, Cyclin D1) as well as decreased live tumor size and mitotic cell count. Metformin-induced activation of AMPK/mTOR pathway was accompanied by decreased microvessel density and vascular endothelial growth factor expression. More importantly, metformin treatment inhibited the growth of metastatic nodules in the lung and significantly potentiated cisplatin-induced cytotoxicity resulting in approximately 90% reduction in tumor growth compared with treatment by either of the drugs alone. Collectively, our data show for the first time that, in addition to inhibiting tumor cell proliferation, metformin treatment inhibits both angiogenesis and metastatic spread of ovarian cancer. Overall, our study provides a strong rationale for use of metformin in ovarian cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yun, H., Lee, M., Kim, S. S., & Ha, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412994200 · Cited by 162
RetractedJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“[6] and also found at the National Cancer Institute Web site (http://dtp.”
BackgroundHirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“In prostate cancers, metformin treatment resulted in decreased proliferation by cyclin D1 [12].”
BackgroundMetformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 3×
“Several in vivo–based studies have demonstrated that metformin can effectively inhibit growth of colon, pancreatic, mammary adenocarcinomas, and lung carcinoma cells in AMPK-dependent and -independent mechanisms [4].”
BackgroundAnisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Nagata, D., Mogi, M., & Walsh, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300643200 · Cited by 331
Prevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 327
Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A., & Vanderhyden, B. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.013 · Cited by 278
Cited by
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
Song, C. W., Lee, H., Dings, R. P. M., Williams, B., Powers, J., Santos, T. D., Choi, B.-H., & Park, H. J. (2012) · Scientific Reports · doi:10.1038/srep00362 · Cited by 280
Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
Giri, S., Karakoti, A., Graham, R. P., Maguire, J. L., Reilly, C. M., Seal, S., Rattan, R., & Shridhar, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054578 · Cited by 273
Self-citationStorozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
Shen, S., Wang, G., Zhang, R., Zhao, Y., Yu, H., Wei, Y., & Chen, F. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.054 · Cited by 257
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018) · Medicine · doi:10.1097/md.0000000000011596 · Cited by 56
Wokoun, U., Hellriegel, M., Emons, G., & Gründker, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5491 · Cited by 45
“Different preclinical studies have demonstrated the anti-neoplastic effects of metformin in animal models of different tumor entities including cancers of the breast (12-17).”
BackgroundAssociation Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer
Yao, K., Zheng, H., & Li, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942380 · Cited by 18
Metadata
- Authors
- Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 13
- Issue
- 5
- Pages
- 483-IN28
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2157000986
- Cited by
- 316
- References
- 22
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.